TriSalus inks SPAC merger to fund cancer trials of pressure-enabled drug delivery technology

TriSalus Life Sciences

TriSalus Life Sciences has identified a path to data on its drug delivery device and lead candidate, inking a deal to merge with a special purpose acquisition company (SPAC) and build an anticipated $60 million cash reserve.

Read more on FIERCE Pharma…

Shanda Consult has been working with SPACs for many years, and our network of SPAC executives has deep experience in the sector. If you need to learn more about how to successfully use a SPAC structure and perhaps wish to set up your own SPAC, we are here to help.

Please contact us with any questions you may have.